Composition and system for the development and evaluation of modified Ghatti rubber and alginate composite microspheres made of aceclofenac

Abstract

Composition for the development of modified Ghatti rubber and alginate composite microspheres of aceclofenac, the composition comprising: 1 g Ghatti gum powder; 1 g sodium hydroxide pellet; 5 g monochloroacetic acid; 6 ml isopropyl alcohol; 100 ml 4% w / v crosslinker; 250-400 mg sodium alginate; and 200 mg Aceclofenac.

Description

Field of the invention:

[0001] The present invention relates to the field of biomedical compositions and systems, as well as drug delivery systems. More specifically, the present invention discloses compositions and systems for developing and evaluating modified Ghatti gum and aceclofenac alginate composite microspheres. Background of the invention:

[0002] Scientists are investigating various biopolymers and their chemically modified form to improve drug bioavailability. As part of these efforts, various polysaccharide-based gums and hydrogels are being explored as drug delivery systems to achieve better results. The mechanism of drug release from these hydrogels generally depends on the optimal combination of cross-linking degree, swelling capacity, hydrogel composition, porosity, stimuli-responsive hydrogel capacity, degradation rate, etc. One of the important properties of the hydrogel is porosity, which directly influences the expansion of the hydrogel and thus the ability to diffuse drug substances with modified release patterns. The pore sizes are easily tailored by varying different compositions of biopolymers in a composite system.Several researchers have already demonstrated that IPN systems, due to their superior properties and activity, can be considered superior approaches as base materials for various biomedical applications, as homopolymers and copolymers alone cannot offer these properties. The use of IPNs as suitable carriers for sustained-release drug delivery systems relies on their ability to release drugs at a controlled rate for precise time intervals.

[0003] Ghatti gum (GhattiG) is the amorphous, semitransparent secretion of the Anogeissus latifolia tree in the Combretaceae family and consists of various high-molecular-weight polysaccharides. Scientists have fully hydrolyzed it and found that it contains L-arabinose, D-galactose, D-mannose, D-xylose, and D-glucuronic acid in a molar ratio of 10:6:2:1:2 and less than 1% 6-deoxyhexose. Ghatti gum is also being studied by some researchers to develop matrix tablets for domperidone and controlled-release formulations using a floating drug delivery system. In addition to this type of modification, scientists have also explored the development of other customized delivery systems using sodium alginate. Interpenetrating polymer network systems are one such system.

[0004] However, no thorough study has yet been conducted to develop suitable dosage forms using ghatti gum or its derivatives. Simple alginate beads have limitations, such as low drug absorption for water-soluble drugs and initial sudden release into the intestinal fluid due to polymer erosion and leaching.

[0005] Therefore, to overcome the above limitations, there is a need to develop a composition and system for the development and evaluation of modified Ghatti gum and alginate composite microspheres of aceclofenac, evaluating the aspects of guar gum as a matrix-forming material with alginate and using hydroxypropyl methylcellulose in combination with alginate to improve the controlled release properties of alginate beads.

[0006] The technical advances disclosed by the present invention overcome the limitations and disadvantages of existing and conventional systems and methods. Summary of the invention:

[0007] The present invention relates to a composition and system for developing and evaluating modified Ghatti gum and alginate composite microspheres of aceclofenac.

[0008] An object of the present invention is to develop a composition and system for developing and evaluating modified Ghatti gum and alginate composite microspheres of aceclofenac.

[0009] Another aim of the present invention is to observe the effect of Ghatti gum and carboxymethyl Ghatti gum in combination with alginate and

[0010] Another aim of the present invention is to investigate the release pattern of aceclofenac from these matrix-based microparticles.

[0011] A composition for developing modified Ghatti gum and alginate composite microspheres of aceclofenac, the composition consisting of the following ingredients: 1 g Ghatti gum powder, 1 g sodium hydroxide pellet, 5 g monochloroacetic acid, 6 ml isopropyl alcohol, 100 ml 4% w / v crosslinking agent, 250-400 mg sodium alginate and 200 mg aceclofenac.

[0012] A system for developing modified Ghatti gum and aceclofenac alginate composite microspheres, the system comprising: a container for mixing 1 g of Ghatti gum powder with 1 g of sodium hydroxide pellet, wherein 6 ml of isopropyl alcohol and 5 g of monochloroacetic acid in 5 parts are slowly added along with double-distilled water to prepare a solution; a beaker of acetone is added to the container with the prepared solution to precipitate the prepared carboxymethyl Ghatti gum (CMGG); a vacuum chamber for placing the container to dry the prepared gum after filtration at 40°C; a stirrer connected to the container for stirring sodium alginate with carboxymethyl Ghatti gum (CMGG) after dispersing it in 20 ml of water, wherein 200 mg of aceclofenac is added to the dispersion to obtain a homogeneous suspension;and a syringe with an injection needle in connection with the stirrer for pouring the suspension dropwise into 100 ml of a 4% w / v solution of a cross-linking agent (calcium chloride / aluminum chloride) to obtain, after drying, composite microspheres of aceclofenac.;

[0013] To further clarify the advantages and features of the present invention, a more detailed description of the invention will be given with reference to specific embodiments thereof, which are illustrated in the accompanying drawings. It should be noted that these drawings represent only typical embodiments of the invention and are therefore not to be considered limiting its scope. The invention will be described and explained in additional detail and in greater detail with reference to the accompanying drawings. Short description of the figure:

[0014] These and other features, aspects, and advantages of the present invention will become more readily understood when the following detailed description is read with reference to the accompanying drawings, in which like characters represent like parts throughout. Fig. Figure 1 shows a block diagram of a system for developing modified Ghatti gum and alginate composite microspheres of aceclofenac.

[0015] Furthermore, those skilled in the art will appreciate that elements in the drawings are shown for convenience and may not necessarily be drawn to scale. For example, the flowcharts illustrate the method by key steps to enhance understanding of aspects of the present disclosure. Furthermore, with respect to device construction, one or more components of the device may have been represented in the drawings by conventional symbols, and the drawing may show only the specific details relevant to understanding embodiments of the present disclosure in order not to clutter the drawings with details that would be readily apparent to those skilled in the art who would benefit from the description herein. Detailed description:

[0016] To facilitate an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and described in specific language. It is to be understood, however, that no limitation on the scope of the invention is intended thereby, since such changes and further modifications of the illustrated system, and such further applications of the principles of the invention as illustrated therein, are contemplated as would normally occur to one skilled in the art to which the invention pertains.

[0017] It will be understood by one skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting thereof.

[0018] References in this specification to "one aspect," "another aspect," or similar expressions mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Therefore, the occurrences of the terms "in one embodiment," "in another embodiment," and similar expressions throughout this specification may or may not all refer to the same embodiment.

[0019] The terms "comprise," "comprising," or other variations thereof are intended to cover non-exclusive inclusion, such that a process or method comprising a list of steps not only includes those steps, but may also include other steps not expressly listed or inherent in such process or method. Likewise, one or more devices or subsystems or elements or structures or components preceded by "comprises...a" does not preclude, without further limitation, the existence of other devices or other subsystems or other elements or other structures or other components or additional devices or additional subsystems or additional elements or additional structures or additional components.

[0020] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The system, methods, and examples provided herein are for illustrative purposes only and should not be considered limiting.

[0021] Embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

[0022] A composition for developing modified Ghatti gum and alginate composite microspheres of aceclofenac, the composition consisting of the following ingredients: 1 g Ghatti gum powder, 1 g sodium hydroxide pellet, 5 g monochloroacetic acid, 6 ml isopropyl alcohol, 100 ml 4% w / v crosslinking agent, 250-400 mg sodium alginate and 200 mg aceclofenac.

[0023] Ghatti gum, sodium alginate, monochloroacetic acid, and sodium lauryl sulfate are purchased from Hi-media, Mumbai. All other reagents are of analytical grade. Double-distilled water is used in all cases.

[0024] Fig. Figure 1 shows a block diagram of a system (100) for developing modified Ghatti gum and alginate composite microspheres of aceclofenac, the system (100) consisting of: a container (102), a beaker (104), a vacuum chamber (106), a stirrer (108), a syringe (110), a hot air oven (112), and a desiccator (114).

[0025] The container (102) is used to mix 1 g of Ghatti gum powder with 1 g of sodium hydroxide pellets, slowly adding 6 ml of isopropyl alcohol and 5 g of monochloroacetic acid in 5 parts along with double-distilled water to prepare a solution. The Ghatti gum powder is frozen overnight. The degree of substitution (DS) is determined by the titrimetric method, and the molar mass of the anhydroglucose unit is 162 g / mol.

[0026] The beaker (104) with acetone is added to the container (102) with the prepared solution to precipitate the prepared carboxymethyl ghatti gum (CMGG).

[0027] The vacuum chamber (106) is used to place the container (102) to dry the produced rubber after filtration at 40 ° C.

[0028] The stirrer (108) is attached to the container (102) to stir sodium alginate with carboxymethyl ghatti gum (CMGG) after dispersing it in 20 ml of water. 200 mg of aceclofenac is added to the dispersion to form a homogeneous suspension. The stirrer (108) mixes the CMGG with sodium alginate for 1 hour at 300 rpm. The stirrer (108) mixes the suspension for 30 minutes at 50 rpm to produce the microspheres.

[0029] An 18-gauge injection needle is connected to the stirrer (108) to pour the suspension dropwise into 100 ml of a 4% w / v solution of a cross-linking agent (calcium chloride / aluminum chloride) to obtain composite aceclofenac microspheres upon drying. The hot air oven (112) is connected to the stirrer (108) to dry the prepared microspheres at 50 °C in a hot air oven. The desiccator (114) is connected to the hot air oven (112) to store the dried microspheres.

[0030] In one embodiment, microspheres are also prepared using alginate and a mixture of alginate-Ghatti gum for comparison. The detailed compositions are listed in Table 1. A total of 10 formulations are prepared to compare drug release from alginate alone, alginate-Ghatti gum composite, and alginate-carboxymethyl. Calcium chloride-crosslinked Ghatti gum IPN system. Table 1: Composition of the alginate-Ghatti gum composite and the alginate-CMGG-IPN microsphere Formulation Code SA (mg) thomas_s (mg) CMGG (mg) Aceclofenac (mg) CaCl2 AlCl3 F 1 400 --- - ---- - 200 5 % --- - F 2 300 100 ---- - 200 5 % --- - F 3 200 200 ----- - 200 5 % --- - F4 250 150 --- - 200 5 % ---- - F 5 300 -- - 100 200 5 % F6 200 - - 200 200 5 % F 7 250 -- - 150 200 5 % F8 300 --- - 100 200 --- - 5 % F9 250 150 --- - 200 - - 5 % F 10 250 150 200 - - 5 %

[0031] SA: sodium alginate, ghatti G: ghatti gum, CMGG: sodium carboxymethyl ghatti gum.

[0032] Degree of Substitution of CMGG Estimation: The formation of a carboxymethyl group in carboxymethyl Ghatti gum is taken into account with minor modifications. Approximately 2 g of the sample is weighed into a 250 ml beaker and 30 ml of ethyl alcohol (95%) is added with stirring to form a good slurry. Then, 3 ml of HNO3 is mixed in with continuous stirring for a few minutes. The slurry is heated with stirring for 5 minutes and then filtered. 20-40 ml of ethanol is used to remove the remaining solids from the beaker. The solid on the filter paper is thoroughly washed with 80% aqueous ethanol to remove traces of acid (tested for neutrality with diphenylamine reagent). The obtained solid is dried in a dryer at 60 °C to constant weight to completely remove the alcohol and then cooled in a desiccator to room temperature. Approximately 0.5 g of the dried solid is accurately weighed into a 500 ml Erlenmeyer flask. 50 ml of water and 20 ml of 0.5 N NaOH solution are added with vigorous shaking. The solution is brought to a boil for 15 to 30 minutes. The remaining liquor is then neutralized to the endpoint while hot with 0.5 N standard HCl using phenolphthalein indicators.

[0033] The degree of etherification is calculated as follows: Degree of etherification=0.162 A / (1−0.058 A) Amount of HCl consumed per gram of sample, 162 = the gram molecular mass of the anhydrous galactose or mannose portion of ghatti gum, 58 = increase in molar mass of anhydro galactose or mannose unit for each carboxy-methyl group formed.

[0034] In one embodiment, the synthesized microspheres are evaluated by FTIR studies. FTIR measurements of Ghatti gum and carboxymethyl Ghatti gum are performed using an FTIR spectrometer (SpectrumBX, serial number -78625, Perkin-Elmer Instruments, USA).

[0035] In one embodiment, differential scanning calorimetry is evaluated. The thermal properties of rubbers are characterized using a 204 F1 Phoenix differential scanning calorimetry (DSC) (Netzsch, Germany). A precisely weighed amount of sample is placed in an aluminum pan in an airtight environment. During measurements in the temperature range of 30–450 °C, a nitrogen atmosphere (20 ml / min) with a heating rate of 5 °C / min is used.

[0036] A scanning electron microscope (SEM) analysis is performed. The purpose of the SEM study is to obtain topographical properties of the polymer. SEM images of ALG-GG and ALG-CMGG composite microspheres are taken. These samples are mounted on the SEM instrument, and scanning is performed using a JEOL-JSM-6360 scanning electron microscope (Jeol Datum Ltd, Tokyo, Japan).

[0037] A mucosal adhesion study is conducted. The mucosal adhesion strength of the microspheres to the mucosa is determined using goat intestine. Briefly, 3 x 5 cm2 pieces of goat intestine are placed on a microscope slide. 500 mg of the formulated microspheres are slowly applied to the intestinal mucosa to ensure proper adhesion to the intestinal surface. Under these conditions, the entire system is maintained at 37°C for half an hour. Afterward, the microscope slide is held at a 45° angle to the plane. Distilled water is allowed to flow through the intestinal membrane from above. At several intervals, the residual solution is collected and filtered. The number of microspheres adhering to the intestinal membrane is recorded, and the mucosal adhesion is expressed as a percentage.

[0038] In vitro drug release and release kinetics studies are conducted for the present invention. Drug release from microspheres / microparticles containing drug-loaded polymers is investigated in both acidic and alkaline dissolution media to simulate gastrointestinal (GIT) conditions using a USP Type 1 paddle-type dissolution test machine (Veego VDA-6D, Veego Instruments Cooperation, Mumbai) under sinking conditions. Initially, an acidic medium is used for 2 hours, and then the remaining microspheres are added to a buffer system with a pH of 6.8. Dissolution of the microspheres is initially performed in acidic media, and then the remaining microspheres and their disintegrated fractions are collected by filtration and added to simulated intestinal fluid. Dissolution is continued for a further 10 hours. The conditions are agitation speed: 50 rpm, temperature: 37 ± 0 °C.5 °C and time interval for buffer withdrawal: 1 hour.

[0039] Volume of solution withdrawal: 10ml.

[0040] The samples are analyzed with a UV-VIS spectrophotometer at λ max 276 analyzed.

[0041] Drug release mechanism and kinetics: The mechanism and in vitro release kinetics of a microparticle can be described by the Koresmeyer-Peppas power law expression, which represents that the amount of drug released per unit area is directly proportional to time. The Koresmeyer-Peppas power law expression is expressed by the following empirical equation: Mt / Ma=Ctn

[0042] M t = Mass of aceclofenac released at time t, M a= mass of aceclofenac released after infinity, K = represents a proportional constant that influences the structural and geometric properties of the formulation. t = time, n = empirical values ​​denote the diffusion exponent, which indicates the mechanism of drug release.

[0043] To evaluate the mechanism of drug diffusion from multiple polymer formulations, the release data are set in the logarithmic form of the Koresmeyer-Peppas law equation and the n-value is calculated from the slopes of the straight lines. Log [Mt / Ma]=logk+nlogt.

[0044] The correlation between n-value and the drug release mechanism through a polymer block is shown in the following table: Table 2: Korsmeyer-Peppas model of diffusion trends Diffusion exponent (n) Type of transport 0.5 Normal Fickian diffusion 0.5<n<1.0 Non-Fickian diffusion (anomalous) 1.0 Case II Transport / Relaxation - controlled release n>1.0 Super Case II Transport

[0045] To support the results obtained from the empirical power law equations, the data were also fitted into different models such as zero-order, first-order, Fick's diffusion law, etc.

[0046] The modification of Ghatti gum is evaluated by preparing carboxymethylated gum from the Ghatti gum by useful modification with the methods of attaching a pendant carboxylic acid unit (-COOH) to the local gum structures. GhattiG-OH + NaOH → GhattiG-O - Na + +H2O GhattiG-O-Na + +ClCH2 COOH → NaCl+GhattiG-O-CH2 COO - Na +

[0047] An unwanted step can also happen as follows NaOH + ClCH2 COO-Na + → HO-CH2 COO-Na + + NaCl

[0048] The degree of substitution for this reaction is measured by the amount of substitution of the carboxymethyl residue. The degree of substitution is calculated based on the normal number of modifications per anhydroglucose unit. Each anhydroglucose residue has hydroxyl groups at three carbon positions at 2, 3, and 6. The degree of substitution can therefore range from zero to three. Previous studies have shown that the substitution is in the ratio C2 > C6 >C3. According to researchers, the basic structure of Ghatti Gum consists of various polysaccharides such as mannose, arabinose, xylose, galactose, and glucuronic acid. The main structure also contains sequentially arranged 4-O- and 2-O-derivatives of the D-mannose-pyranose ring and chains of 1 → 6-linked D-galactose-pyranose rings with branching derivatives of l-arabinofuranose. Therefore, the expected degree of derivatization, which estimates the normal degree of formed derivative of o-carboxymethyl groups per anhydrous polysaccharide ring, should be above 1. However, the degree of substitution is observed in various cases to be 0.42 ± 0.06. These results are comparable to the findings of several researchers in the case of other gums. For example, a comparably low degree of substitution is observed in guar gum, xanthan gum, and locust bean gum.Various researchers studied the structure of Ghatti Gum and found that it has a very complex parent structure with multiple branched chains. Consequently, a higher concentration of sodium hydroxide is required during the etherification of the polymer because two types of reactions take place. Initially, glycolate is formed, but with increasing concentration of sodium hydroxide, the formation of carboxymethylation occurs in the complex polymer backbone of the gum. Steric effects of heavier parts of the gum are expected to additionally interfere with the activity of the carboxymethylation reagent and the hydroxyl group of Ghatti Gum. Therefore, the degree of substitution is not quite as normal. FTIR analysis of Ghatti Gum and its carboxymethyl derivative is performed to confirm the presence of an o-carboxymethyl group in Ghatti Gum.

[0049] Generally, local gums are prepared by the usual method, namely Williamson etherification, carboxymethylated and the modification of Ghatti gum is confirmed by supernatural FTIR analysis.

[0050] IPN microspheres and drug encapsulation efficiency (DEE) are investigated. When the alginate-CMGG drug dispersion is dropped into a CaCl2 or AlCl3 solution, ionic cross-linking occurs between the SA and CMGG strands. During ionic cross-linking, Ca2+ ions or Al3 replace + the Na + -ions of SA and CMGG at the carboxylate group and different chains of SA and / or CMGG were treated with Ca2 + / Al3 + connected to form the link. Thus, the Ca2 +Ions are combined with two SA or CMGG chains to form a spherical matrix that encapsulates uncrosslinked polymer and drug. When such ionically crosslinked microspheres are formed, intrapenetrating chains with a polymeric network structure develop.

[0051] DEE ranges between 80.42 ± 0.098% and 93.33 ± 0.063%. The percentage entrapment efficiency showed a dependence on the amount of GhattiG / CMGG. For Ghatti gum, the maximum entrapment efficiency was observed at a 5:3 ratio between alginate and Ghatti gum, while the ratio for alginate and CMGG is 1:1. Aluminum chloride as a crosslinker is also more effective than calcium chloride, which may be due to the formation of a stiffer structure in the gum in the presence of trivalent Al3+ ions:

[0052] The size of the microspheres varies between 792 and 901 µm. The viscosity of the GhattiG solution is lower than that of the SA solution, but when it is added to an SA solution, the viscosity of the SA / GG mixed solution increases synergistically. However, it is also evident that the viscosity of the mixed system is higher than that of the individual system due to the interaction between SA and GhattiG or CMGG molecules. Thus, increasing the amount of Ghatti rubber and CMGG resulted in a larger microsphere size, which led to the formation of larger droplets during extrusion through the needle, which in turn resulted in a larger microsphere size. Again, the size of the microspheres decreases when Al 3+ -ions are used. Crosslinking causes the polymer matrix to shrink rapidly, resulting in smaller and stiffer IPNs with a high crosslink density.

[0053] Muco-adhesion studies showed that the addition of Ghatti Gum or Carboxymethyl Ghatti Gum did not significantly improve this property of alginate microspheres. Table 3: Drug entrapment efficiency (%DEE) and average particle size values ​​of all formulations (n=3) Recipe code Average %DEE value ± SD Particle size (µm) F1 80.42 ± 0.098 825 ± 2.02 F2 85.79 ± 0.002 833 ± 2.35 F3 89.57 ± 0.002 892 ± 1.04 F4 93.33 ± 0.063 901 ± 1.41 F 5 85.12 ± 0.012 820 ± 1.23 F6 89.46 ± 0.002 881 ± 1.54 F7 84.84 ± 0.002 875 ± 2.43 F8 90.45 ± 0.002 792 ± 1.31 F9 88.93 ± 0.005 891 ± 2.31 F10 89.26 ± 0.009 859 ± 1.31

[0054] Scanning electron microscopy (SEM) is performed on the synthesized samples. SEM micrographs of alginate-Ghatti gum and alginate-modified Ghatti gum are taken at 60x magnification. The microspheres have a smooth and dense surface and are held together by a rigid polymer network with a less porous structure, possibly due to the better intercalation of alginate and Ghatti gum to form a homogeneous composition. A smooth surface and very few surface wrinkles are observed, but in the case of the alginate-CMGG-IPN microspheres, no surface roughness is present. The microspheres may have shrunk upon higher cross-linking, resulting in the formation of microspheres with a smoother surface and surface wrinkles. The homogeneity is much more pronounced in alginate-CMGG microspheres. This may be due to the higher solubility and alkaline nature of CMGG.

[0055] Alginate-Carboxymethyl Ghatti Gum Composites: Differential scanning calorimetry (DSC) is performed. The DSC thermograms of Ghatti Gum and Carboxymethyl Ghatti Gum are analyzed. The crystal point is obtained in the DSC thermograms of Ghatti Gum. However, in the case of the DSC thermogram of Carboxymethyl Ghatti Gum, the higher structural stability of CMGG makes it less heat-resistant.

[0056] An in vitro drug release study is conducted. The in vitro drug release profile from alginate beads, alginate-ghatti gum, and modified ghatti gum is compared. With normal alginate beads, most of the drug is released within 6 hours at a pH of 6.8, but very little drug release is observed in acidic media. However, when ghatti gum is used, the release is delayed to 12 hours or more. The initial sudden release from alginate beads due to the large gel porosity is prevented by the use of ghatti gum. This is evident from all the results. A higher concentration of ghatti gum caused a greater delay. However, when carboxymethyl ghatti gum was used together with alginate in the presence of calcium chloride, both gums cross-linked to form an IPN structure.The formation of IPN further delayed the release of the drug from the microparticles. In formulations F8, F9, and F10, the effect of aluminum ions is pronounced because it is a trivalent ion, compared to calcium, which is a divalent ion. Aluminum ions can again delay the release of the drug compared to calcium ions.

[0057] A study of the mechanism and rate of drug release is conducted. The in vitro release profiles of the formulations are fitted into various models and analyzed. The resulting in vitro drug release data are fitted into various kinetic models such as zero-order, first-order, Higuchi's model, and Korsmeyer's. Peppas' equations.

[0058] Since many release processes are also represented by mixed kinetics, both Fickian and non-Fickian diffusion mechanisms and sometimes also relaxation- or dissolution-based release kinetics are pursued.

[0059] A drug transport mechanism generally referred to as Case II of relaxing release, when drug release is caused by stresses and state transitions in hydrophilic glassy polymers after their swelling in water or gastrointestinal fluids. This also occurs due to biopolymer unraveling and wear. From the model based on the Korsmeyer-Peppas equation, the value of the Rug release exponent (n) of aceclofenac sodium is between 1.07 and 1.1, indicating that drug release from the polymers follows non-Fickian diffusion (anomalous) and relaxing drug release. The results show that they also follow zero-order kinetics and might follow the Weibul model to some extent. Thus, there is a possibility of polymer erosion.The mean dissolution time is also high when using aluminum chloride, as well as carboxymethyl Ghatti gum. This proves that IPN formation occurs during cross-linking of carboxymethyl cellulose and alginate with calcium chloride or aluminum chloride.

[0060] The drawings and the foregoing description provide examples of embodiments. Those skilled in the art will recognize that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be separated into multiple functional elements. Elements from one embodiment may be added to another embodiment. For example, orders of the processes described herein may be changed and are not limited to the manner described herein. Furthermore, the actions of any flowchart need not be implemented in the order shown; nor do all actions necessarily need to be performed. Also, those actions that are not dependent on other actions may be performed in parallel with the other actions. The scope of the embodiments is in no way limited by these specific examples.Numerous variations, whether explicitly stated in the specification or not, such as differences in structure, dimensions, and use of materials, are possible. The scope of the embodiments is at least as broad as indicated in the following claims.

[0061] Advantages, other benefits, and solutions to problems have been described above with reference to specific embodiments. However, the advantages, benefits, solutions to problems, and any components that may cause an advantage or solution to occur or become more apparent are not to be construed as a critical, required, or essential feature or component of any or all of the claims. REFERENCES 100 A system for developing modified Ghatti gum and alginate composite microspheres of aceclofenac. 102 containers 104 cups 106 Vacuum Chamber 108 stirrers 110 syringe 112 Convection oven 114 Desiccator

Claims

[1] Composition for developing modified Ghatti gum and alginate composite microspheres of aceclofenac, the composition comprising: 1 g Ghatti gum powder; 1 g sodium hydroxide pellet; 5 g monochloroacetic acid; 6 ml isopropyl alcohol; 100 ml 4% w / v crosslinker; 250-400 mg sodium alginate; and 200 mg aceclofenac. [2] A system (100) for developing modified Ghatti gum and alginate composite microspheres of aceclofenac, the system (100) comprising: a container (102) for mixing 1 g of Ghatti rubber powder with 1 g of sodium hydroxide pellet, slowly adding 6 ml of isopropyl alcohol and 5 g of monochloroacetic acid in 5 parts together with double distilled water to prepare a solution; a beaker (104) containing acetone is added to the container (102) containing the prepared solution to precipitate the prepared carboxymethyl ghatti gum (CMGG); a vacuum chamber (106) for placing the container (102) to dry the produced rubber after filtration at 40 ° C; a stirrer (108) attached to the container (102) for stirring sodium alginate with carboxymethyl gum (CMGG) while dispersing it in 20 ml of water, 200 mg of aceclofenac being added to the dispersion to form a homogeneous suspension; and a syringe (110) equipped with an injection needle, in conjunction with the stirrer (108) for pouring the suspension dropwise into 100 ml of a 4% (weight / volume) solution of a cross-linking agent (calcium chloride / aluminium chloride) to obtain, after drying, composite microspheres of aceclofenac. [3] The system according to claim 2, wherein the Ghatti gum powder is frozen overnight. [4] The system of claim 2, wherein the stirrer (108) mixes the CMGG with sodium alginate at 300 rpm for one hour. [5] The system of claim 2, wherein the stirrer (108) mixes the suspension at 50 rpm for 30 minutes to produce the microspheres. [6] System according to claim 2, characterized by a hot air oven (112) connected to the stirrer (108) for drying the produced microspheres at 50 °C in a hot air oven. [7] The system of claim 2, wherein a desiccator (114) for storing the dried microspheres is connected to the hot air oven (112).

Images